Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY24 results · Jul–Sep 2023
Ajanta Pharma reported revenue from operations of ₹1,028.44 crore (up 9.6% from Q2 FY23) and net profit of ₹195.30 crore (up 24.7% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,028.44 | 938.10 | +9.6% | 1,021.04 | +0.7% |
| Other income | 21.33 | 40.35 | −47.1% | 31.75 | −32.8% |
| Total income | 1,049.77 | 978.45 | +7.3% | 1,052.79 | −0.3% |
| Profit before tax | 275.94 | 203.00 | +35.9% | 269.04 | +2.6% |
| Net profit for the period | 195.30 | 156.60 | +24.7% | 208.12 | −6.2% |
| EPS, basic (₹) | 15.51 | 12.22 | +26.9% | 16.53 | −6.2% |
| Net margin (%) | 19.0 | 16.7 | 20.4 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 945.18 | 837.23 | +12.9% | 1,014.58 | −6.8% |
| Other income | 52.16 | 78.37 | −33.4% | 31.46 | +65.8% |
| Total income | 997.34 | 915.60 | +8.9% | 1,046.04 | −4.7% |
| Profit before tax | 290.50 | 206.59 | +40.6% | 275.37 | +5.5% |
| Net profit for the period | 212.36 | 167.18 | +27.0% | 212.04 | +0.2% |
| EPS, basic (₹) | 16.87 | 13.05 | +29.3% | 16.84 | +0.2% |
| Net margin (%) | 22.5 | 20.0 | 20.9 |
Consolidated
- Filed with BSE
- 01 Nov 2023, 11:16 IST
- Board meeting
- 31 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Nov 2023, 11:16 IST
- Board meeting
- 31 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE